Identification and evaluation of clinically significant prostate cancer: a step towards personalized diagnosis

DOI:

[10.1097/MOU.0000000000000385](https://doi.org/10.1097/MOU.0000000000000385)

Document Version

Accepted author manuscript

[Link to publication record in Manchester Research Explorer](#)

Citation for published version (APA):

Ali, S. A., Hoyle, A., Baena Chaparro, E., & Clarke, N. (2017). Identification and evaluation of clinically significant prostate cancer: a step towards personalized diagnosis. *Current Opinion in Urology*, 27(3), 217-224. <https://doi.org/10.1097/MOU.0000000000000385>

Published in:

Current Opinion in Urology

Citing this paper

Please note that where the full-text provided on Manchester Research Explorer is the Author Accepted Manuscript or Proof version this may differ from the final Published version. If citing, it is advised that you check and use the publisher's definitive version.

General rights

Copyright and moral rights for the publications made accessible in the Research Explorer are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

Takedown policy

If you believe that this document breaches copyright please refer to the University of Manchester's Takedown Procedures [<http://man.ac.uk/04Y6Bo>] or contact uml.scholarlycommunications@manchester.ac.uk providing relevant details, so we can investigate your claim.

Title: Identification and evaluation of clinically significant prostate cancer: A step towards personalized diagnosis.

Authors: A Ali (1,3), A Hoyle (2,3,4), E Baena (1,3), NW Clarke (2,3,4,5*)

¹ Prostate Oncobiology, Cancer Research UK Manchester Institute, University of Manchester, Wilmslow Road, Manchester, M20 4BX, United Kingdom.

² Cancer Research UK Manchester Institute, University of Manchester, Wilmslow Road, Manchester, M20 4BX, United Kingdom

³ Belfast-Manchester Movember Centre of Excellence, Cancer Research UK Manchester Institute, University of Manchester, Wilmslow Road, Manchester, M20 4BX, United Kingdom

⁴ Department of Surgery, The Christie NHS Foundation Trust, Wilmslow Road, Manchester, M20 4BX, United Kingdom

⁵ Department of Urology, Salford NHS Foundation Trust, Stott Lane, Salford, M6 8HD, United Kingdom

***Corresponding author:**

Professor Noel W. Clarke

Department of Surgery,
The Christie Hospital, Wilmslow Road, Manchester M20 4BX,
United Kingdom
E-mail: noel.clarke@christie.nhs.uk

Abstract

Purpose of review:

Prostate cancer diagnostics are evolving rapidly. The quest to differentiate “clinically significant” from “clinically insignificant” disease has gathered momentum, leading to substantial change in traditional diagnostic approaches. Herein we review the relevant information on currently available biomarkers and assess their ability to help physicians and patients in making a shared and personalised decision based on their individual risk of harbouring clinically significant disease.

Recent findings:

Serum, urine, tissue and imaging biomarkers have been evaluated to improve the identification of clinically significant disease and this international effort has yielded promising, but not always consistent results. Changes in MR imaging technology have realized a quantum change and this facility is now becoming more widely incorporated into diagnostic and disease risk-stratification protocols. However, standardization and further validation is required.

Summary:

Acceptance and widespread adoption of serum, urine and genetic markers is awaited but novel and promising techniques alone and in combination have emerged. With validation and further focus these may be adopted more widely.

Keywords

Prostate cancer, biomarkers, genomics, multiparametric magnetic resonance imaging

Keypoints

1. Personalized risk stratification should be used when considering testing for, and biopsy of the prostate to detect clinically significant prostate cancer.
2. Although multiparametric magnetic resonance imaging (mpMRI) is beneficial in biopsy negative patients suspected of harbouring prostate cancer, it's utility in avoiding prostate biopsy needs further evaluation. The use of concurrent novel biomarkers may strengthen its use in diagnosis and risk stratification in the future.
3. Newer tissue based molecular prognostic tests have to be interpreted cautiously keeping in mind the multifocal and heterogeneous nature of prostate cancer.
4. Newer blood based biomarkers such as the 4kscore and PHI are promising, but clear cut-offs are lacking for diagnosis of significant disease.

Introduction

The importance of cancer biomarkers is exemplified by the development and clinical use of prostate specific antigen (PSA) testing in prostate cancer (PCa). Since its discovery PSA's use became internationally ubiquitous within 10 years and its use in screening and case finding is mainly responsible for the increased detection, and documented clinical incidence of this disease, particularly in the developed world (1). Whilst early detection may be important, the PSA story highlights another problem, that of over-detection and overtreatment (2). The classic paper by Franks showed that "indolent" PCa was commonly present and with increasing frequency as men aged (3). It has taken the publication of 2 large trials nearly 60 years later to reaffirm the notion that many patients diagnosed have "clinically insignificant" disease which can be observed quite safely without the need for intervention with surgery or radiotherapy (2, 4). Thus, the concept of clinically "insignificant" versus "significant" PCa has been "rediscovered"; but in modern practice are we sufficiently confident that we can discriminate between the two? Various criteria for defining clinically significant and insignificant PCa exist (5) but can they identify clinically significant PCa accurately? In this review, we discuss the *status quo* regarding the ability of serum, urine, tissue and imaging biomarkers to make this distinction.

Risk stratification

The decision to pursue identification of potentially curable PCa in age-eligible men is complex and controversial. It involves consideration of a person's age, race, family history, personal history, comorbidities, life expectancy and personal preferences. Therefore, the first step in identifying clinically significant PCa in age-eligible asymptomatic men should be to counsel them prior to PSA testing (6-8), thereby informing them of the possibility of detection of low-grade cancer in relation to their life expectancy and risk of disease progression. Tools are available for this (9) and in elderly, co-morbid patients unnecessary biopsies can be avoided, particularly with the use of adjunctive tests (10). Similarly, where there is high risk, more detailed investigation can be encouraged. This is particularly important in men with inherited high risk, such as African-Americans and men with a family history of a first-degree relative with PCa. African-American men have a higher incidence and mortality compared with Caucasian men (11) and men with first-degree relatives with PCa have a substantially increased risk (12-14).

Men from BRCA gene mutation affected families are also susceptible to the development of aggressive, clinically progressive disease. Germline mutations in BRCA1, BRCA2 or DNA mismatch repair genes are known to be associated with increased PCa risk, with a 6.3 and 3.67 fold chances of developing PCa respectively (15, 16). Those with BRCA mutations have a more aggressive phenotype and significantly reduced survival (17-19).

Blood and urine based biomarkers

PSA is currently the first-line blood based biomarker for PCa detection and risk stratification. It is a continuous biomarker, and prostate, but not PCa specific. There is no value below which the risk of Gleason score (GS) ≥ 7 cancer is zero and the risk of aggressive cancer increases with increasing level (20). Table 1 lists PSA along with other select biomarkers and their sensitivity specificity for detecting clinically significant cancers (21-27). Age specific and race-specific cut-offs have been proposed with some utility by several studies (28, 29) but the role of these specific cut-offs in current practice remains unclear.

PSA kinetics, namely velocity and doubling time are of value. PSA velocity (PSAV) is the absolute annual increase in serum PSA (ng/mL/year), whilst PSA doubling time (PSADT) measures the exponential increase in serum PSA over time. These measurements have been investigated in various studies with conflicting results in their ability to predict the presence of cancer or its aggressiveness (eg identification of Gleason score ≥ 7). Currently, PSAV and PSADT have a prognostic role after treatment but a limited role in diagnosis (30, 31). Another PSA based measurement, PSA density (PSAD) is calculated as serum PSA divided by prostate volume. PSAD is helpful in identifying patients with high PSA secondary to benign prostatic hyperplasia (BPH). It has been found to correlate with aggressiveness (32) but its utility is limited due to lack in the precision of prostate volume measurement.

Free PSA (fPSA) is the unbound fraction of PSA in blood and the ratio of fPSA:total is commonly used in clinical practice. However, it is not a specifically accurate test for diagnosis or biological aggression. Its value is also affected by external factors such as temperature and appropriately reliable and repeatable cut-off thresholds have been difficult to produce (33). fPSA use has therefore been developed further: it forms a part of two recently introduced blood-based markers, the 4Kscore and the prostate health index (PHI). The 4Kscore is a prediction model, which integrates clinical variables (age, prior biopsy, digital rectal examination (DRE) results) and levels of four kallikreins: total PSA, fPSA, intact PSA and human kallikrein 2. It generates a score that predicts the patient's risk of GS ≥ 7 on biopsy. It has been evaluated in multiple studies for prediction of GS ≥ 7 on biopsy, risk of upgrading on RP and risk of development of metastatic disease (22, 34). Another blood-based test is PHI, which combines total PSA, fPSA and serum isoform [-2]proPSA using a mathematical equation: $([-2]proPSA/fPSA) \times \sqrt{PSA}$. PHI has also been tested in multiple studies and has been found to predict GS ≥ 7 on biopsy, upgrading/upstaging on prostatectomy and recurrence (23). Both, these tests have shown promising preliminary results in guiding decisions for initial and repeat biopsy. However, these tests rely inherently on the use PSA, and clear cut-offs have not yet been set. Another recently reported test, the "Stockholm-3" test (10) uses fPSA in combination with an array of other PCa risk associated factors (PSA, free PSA, intact PSA, hK2, MSMB, MIC1), genetic polymorphisms (232 SNPs), clinical variables (age, family, history, prostate examination and previous prostate biopsy). This test performed significantly better than PSA alone for detection of cancers with a Gleason score of at least 7 and claimed the potential "to reduce unnecessary biopsies without compromising the ability to diagnose PCa with a Gleason score of at least 7", However, this test needs to be validated in large scale independent studies before its use can be recommended more generally.

Urine based biomarkers include PCA3, TMPRSS2:ERG and the Mi-Prostate Score (MiPS). PCA3 is a non-coding RNA that is measured after digital rectal examination (DRE). It was FDA approved in 2012 for patients with initial negative biopsy and high suspicion of PCa but current studies have reported conflicting results in its association with clinically significant disease (24, 35-37). TMPRSS2:ERG is a gene fusion associated with the early onset of PCa. Its implications in clinical practice remain unclear, with studies demonstrating conflicting data in predicting biochemical recurrence following radical prostatectomy (38, 39). Evaluation of TMPRSS2:ERG within an active surveillance group has shown an association with progression risk (58.6 Vs 21.7%; HR: 2.45)(40) but this remains un-validated. MiPS combines urine PCA3 and TMPRSS2:ERG to serum PSA level to generate a risk score. It predicts the presence of PCa and high-grade PCa on biopsy (41). The uncertainty in using these biomarkers is reflected in their adoption by national and international guidelines for PCa diagnosis and treatment: the NCCN and EAU guidelines recommend PCA3 and PHI usage, whilst NICE has recommended against their use (6, 8, 42).

Tissue markers

Gleason grading is an indispensable risk stratification system based on the microscopic appearance of glandular architecture. Initially proposed in 1966, it has been incorporated into various risk stratification algorithms (43). More recently, in 2005 and 2014, the International Society of Urological Pathology (ISUP) consensus conferences updated this PCa grading system. A new five-tiered prognostic grade grouping (PGG) system was adopted with 90% consensus at the 2014 ISUP (44). Five Gleason score groups were considered: ≤ 6 ; $3 + 4 = 7$; $4 + 3 = 7$; 8; and 9–10 as PGG 1 to 5 respectively. This new revision makes distinction between Gleason 3+4 and 4+3 and separates them as two different entities with distinct clinical outcomes. Subsequently, in 2016 different studies have reported and validated that each PGG is associated with a different risk of biochemical recurrence, metastatic free survival and PCa specific death (45–47). Furthermore, Rubin et al. (48*) investigated and reported the genomic correlates to the PGG in a pooled cohort of 426 PCa cases. Of these 426 tumors, none of the 74 belonging to PGG 1 (Gleason ≤ 6) exhibited polyploidy and they harbour very few gene amplifications as compared to PGG 2–5. Interestingly, there was no significant difference in the number of aberrant genes between PGG 4 and PGG 5, suggesting that the reported difference in clinical outcomes in PGG 4 and PGG 5 could be due to epigenetic changes or currently undescribed alterations.

Tissue based molecular prognostication assays

A number of molecular assays have been developed recently to assess the genome, methylation status, transcriptome or proteome for prognostication in PCa. These tests aim to further discriminate newly diagnosed PCa in to low and intermediate risk categories.

Oncotype DX PCa test (Genomic Health Inc., Redwood City, CA, USA) is a RT-PCR gene expression assay. It is used to predict primary Gleason pattern 4, any Gleason 5 pattern, pT3 disease, or BCR in NCCN low to intermediate risk patients (49). It comprises 5 housekeeping genes and 12 genes involved in four tumorigenic pathways: the androgen pathway (AZGP1, KLK2, SRD5A2, and FAM13C), stromal response (BGN, COL1A1, and SFRP4), proliferation (TPX2) and cellular organization (FLNC, GSN, TPM2, GSTM2) (50). Prolaris (Myriad Genetics, Inc.) is another qRT-PCR based gene expression assay which measures the proliferative index and predicts PCa specific death. It evaluates 15 housekeeping genes and 31 cell cycle related genes. ProMark (Metamark Genetics) is an 8 protein based signature (CUL2, SMAD4, PDSS2, HSPA, DEL2L1, pS6, YBOX1 and FUS). It is used for predicting two co-primary end-points: (i) Gleason $\geq 4+3$ or non-organ confined disease, (ii) Gleason $\geq 3+4$ or non-localized disease. It analyses the region of interest using a quantitative multiplex immunofluorescence platform. Currently, Oncotype DX and Prolaris are recommended post diagnostic biopsy as a part of NCCN guidelines for use in patients with very-low to low risk PCa and a 10–20 year life expectancy (8). They are not currently used regularly in general urological practice outside the US.

Imaging as a biomarker

The development of multiparametric MRI (mpMRI) has shifted the focus of MRI from local staging of PCa to the detailed characterisation of primary prostatic lesions. This has generated considerable interest and debate as a non-invasive imaging biomarker with the promise of improving detection of clinically significant disease through targeted biopsies and reduction in the detection of clinically insignificant cancer.

Prostate imaging reporting and data system (PIRADS) scoring

To standardise the acquisition parameters, interpretation, grading and reporting of mpMRI in PCa, PIRADS was initially proposed in 2012. This has now been replaced with the more robust PIRADsv2 guidelines (51). However, there are still potential gaps and concerns regarding interpretation and scoring that need addressing (52). Moreover, the revised PIRADsv2 has only moderate inter-observer agreement and accuracy for detection of clinically significant disease (53). Good quality pictorial atlases from high volume centres enabling further refinement in interpretation guidelines are still required and indeed, some leading PCa research groups have not adopted PIRADS scoring because of concerns about its interpretation and reliability.

Can mpMRI avoid biopsy in insignificant prostate cancer?

A recent meta-analysis concluded that mpMRI detects clinically significant cancers with a sensitivity, specificity and negative predictive value (NPV) of 58-96%, 23-87% and 63-98% respectively (25). This meta-analysis only included studies using PIRADS scoring and therefore only one study which used patient specific whole mount post-RP analysis as a reference standard was included. Another recent study, which used PIRADsv2 as scoring criteria, reported correct identification of 94-95% PCa foci $\geq$ 0.5ml. While, this study was an unblinded retrospective analysis, an important caveat demonstrated was the study's inability to detect 75% of lesions with GS $\geq$ 4+3 which were <0.5 ml (54). This highlights a significant limitation of the use of mpMRI for screening and AS. Other studies used post-RP cross-sectional analysis as a reference standard and evaluated mpMRI in a blinded manner using the Likert scale(26, 27). These data highlight the fact that although mpMRI has a high NPV depending on the prevalence of PCa in the screened population, it also misses significant cancers, particularly small, high-grade lesions (Table 1).

mpMRI is now widely incorporated within diagnostic protocols for its role in guiding diagnostic intervention, particularly in patients with previous negative biopsy and high suspicion of PCa. It has the potential to improve detection of clinically significant disease through targeted biopsies whilst reducing the detection of clinically insignificant cancer. mpMRI has also seen widespread incorporation within AS protocols, but the current data about its long-term accuracy is lacking and robust evaluation studies are required to define radiographic progression in patients on surveillance programmes (55). A recent study evaluated 207 men undergoing MRI fusion biopsy during AS. The authors reported that MRI-ultrasound fusion biopsy increased the upgrading in AS patients and in a small subset of patients missed by systematic biopsy, upgrading also occurred in areas outside MRI targeted biopsy fields, suggesting that systematic sampling should also be offered (56). Understanding of the utility of mpMRI has improved with the publication of the PROMIS trial (57, 58*). It reported the accuracy of mpMRI in differentiating between insignificant and significant PCa, defined as Gleason $\geq 4+3$ and/or maximum cancer core length ≥ 6 mm, proposing that this methodology might enable the avoidance of "unnecessary" prostate biopsies in men with mpMRI defined insignificant disease. The results have generated significant debate. The study evaluated 576 men with a raised PSA up to 15ng/mL. Each underwent an mpMRI which was followed by TRUS guided and template guided core prostate biopsies. The results for mpMRI published a sensitivity of 93% (95%CI 88-96), specificity of 41% (36-46), positive predictive value 51% (46-56) and negative predictive value of 89%. TRUS biopsy demonstrated significantly less sensitivity than mp-MRI; 48% (95%CI 42-55) ($p \leq 0.0001$) and had a significantly worse negative predictive value than mp-MRI; 74% (69-78) vs 89 (83-94) ($p \leq 0.0001$) (although TRUS biopsies were performed immediately after template biopsies in this study, potentially reducing their accuracy). It was concluded that the TRUS biopsy alone is no longer an appropriate method for diagnosing "significant disease", and the authors proposed two

strategic approaches: using mpMRI alone as a triage tool to avoid biopsies in 27% of men (with 2% fewer clinically significant cases being detected) and using biopsy targeted to mpMRI findings to achieve the sensitivity of template mapping biopsies. According to the authors, triage with mpMRI could avoid primary biopsy in 27% of cases but would detect 3% more cases of clinically significant cancer than standard TRUS biopsy for all pathways. Discussion following publication of the PROMIS trial revolves around the use of mpMRI in patients with clinically significant but low volume disease, defining Gleason 3+4 as “insignificant disease” (particularly in young patients), questioning the trial definition of significant disease in routine clinical practice and accepting a 10% “miss rate” for Gleason 3+4. There is also the issue of applicability of mpMRI results in departments where specialist radiological expertise is not always of the standard seen in a high volume cancer centre. A considerable strength of the study however was its negative predictive value in excluding insignificant disease which might safely be observed.

MRI/Ultrasound Fusion guided prostate biopsies

Image guided biopsies are commonly practised in many other solid urological and non-urological tumours. Unlike other solid tumours, prostate biopsies traditionally rely upon randomly sampling the whole organ. The development of mpMRI technology has enabled the identification of prostatic lesions susceptible to targeted biopsy. Fusion technology superimposes mpMRI images onto TRUS software enabling real time dynamic identification of lesions. This greatly assists the clinician in focal biopsy of a prostatic lesion either using standard TRUS, or trans-perineal guided biopsies, depending on lesion location and clinician preference. Studies evaluating this technology have commented that fusion biopsies can detect 30% more significant PCa when compared to standard biopsies and with 17% fewer insignificant cancers (59). The addition of standard biopsies to fusion-targeted biopsies simply increased the insignificant disease pick up rates. Furthermore, similar clinically significant PCa detection rates have been reported irrespective of mpMRI guided biopsy technique (60).

Implications of intra-tumor and inter-tumor heterogeneity

Up to 60-90% cases of PCa are multi-focal in nature (61). Moreover, recent genomic studies have reported inter-tumour and intra-tumour heterogeneity in PCa (62, 63). Liu et. al. using a cohort of 30 men with metastatic disease from a rapid-autopsy program also suggested that metastatic clones may share a monoclonal origin (64). However, the origin of metastatic disease from index lesions is not yet proven conclusively (65, 66). Non-index lesions have also been reported to invade locally and to metastasise (67-69). More recently, Wei et. al. evaluated 26 non-contiguous foci from 4 patients (70*). CNA, WES and RNA-sequencing of these 26 foci revealed considerable intra-tumoral and inter-tumoral heterogeneity. Furthermore, using the gene expression data, the authors generated Oncotype DX, Prolaris and Decipher scores and demonstrated intra-prostatic heterogeneity. The authors concluded that there was widespread genetic diversity between the different PCa foci and a molecular prognostication test from a single biopsy is not sufficient to dictate treatment. Nevertheless, this study had limitations: first it included patients with intermediate to high risk disease that don't accurately reflect the type of patients requiring prognostication; and second, the authors only quantitated genes used in the commercial tests and didn't use the commercial tests themselves. Nonetheless, these studies highlight a critical limitation of using a single core or foci for prognostication using tissue based molecular and imaging tests. Imaging tests might miss high-grade small foci of high malignant potential, and basing a molecular prognostication test based on a mpMRI targeted biopsy may lead to false negative results. Further studies are required exploring and linking the two.

Perfecting imperfect biomarkers

While the quest for elusive “perfect” diagnostic biomarker continues, physicians currently have to rely on sequencing of emerging biomarkers in certain “grey areas”. Due to limited literature on biomarker sequencing, an optimal strategy requires an implicit understanding of sensitivity, specificity and limitations of each individual test to personalize the diagnostic pathway based on clinical priorities. Currently only a few studies have reported on sequencing PCA3 and PHI with mpMRI whilst similar data for 4Kscore is awaited (71-74). A 2015 clinical and cost-effectiveness analysis conducted by the National Institute of Health Research (NIHR) evaluated PCA3 and PHI along with mpMRI (74). This report concluded that the addition of PCA3 or PHI to mpMRI did not have a noticeable impact on diagnosis of prostate cancer in men who are suspected of PCa and in whom the results of an initial biopsy were negative or equivocal. However, a few limitations highlighted by this report were (i) lack of information on sequencing of these tests, (ii) insufficient evidence on appropriate threshold values of PCA3 and PHI for clinical use and (iii) issues due to uncertainty in defining clinically significant and insignificant PCa. More recent studies have attempted to address these concerns and suggest that PCA3 and PHI would primarily benefit in patients with a negative or equivocal mpMRI (PIRADS 1-3) (72, 73, 75). For instance, a study modelled four sequencing combinations of PCA3 and mpMRI in biopsy naïve men (72). The diagnostic pathway with mpMRI followed by PCA3 testing in patients with low to equivocal mpMRI was reported to be the best. This pathway avoided 36.3% biopsies whilst missing 4.9% Gleason ≥ 7 cancers. Cohort studies evaluating the performance of PHI along with mpMRI have also suggested its benefit in patients with negative or equivocal mpMRI (73, 76). Furthermore, in repeat biopsy scenario, a joint consensus statement by the American Urological Association (AUA) and Society of Abdominal Radiology (SAR) have strongly advocated initial mpMRI when optimal imaging is possible, while reserving ancillary markers (PCA3, PHI and 4Kscore) for patients with PIRADSV2 score 1-2 (77). Table 2 summarizes their potential role in evolving diagnostic pathway.

However, the issues of prioritizing in the initial biopsy setting remain unresolved. Prioritizing blood and urine based biomarkers without mpMRI, risks limitation relating to imprecise biopsy techniques whilst “scan all, biopsy only visible, avoid invisible” scenario risks of missing aggressive PCa. Therefore, a two-tiered approach in patients with PSA 3-10 ng/mL might be more appropriate to strike a balance. Current NCCN guidelines state that 4Kscore and PHI may be beneficial in “grey areas” but also points out that mpMRI may maximize detection of aggressive disease in the initial biopsy setting (with reservations about its routine usage) (8). Sequencing these biomarkers to maximize clinically significant PCa detection, minimize insignificant PCa findings in a cost-effective, reliable population based setting still requires further study before a consensus on their use can be agreed.

Conclusion

The future of PCa diagnostics will continue focus on improving the yield of clinically significant disease whilst minimising the invasive nature of tests which often result in the diagnosis of biologically insignificant disease. For these changes to occur a consensus needs to be sought regarding the definition of clinically significant PCa to drive these changes. This consensus is currently some way off.

Traditional diagnostic protocols have begun to incorporate modern diagnostic techniques including the widespread adoption of mpMRI into routine PCa diagnostics, with increasing investment and availability of mpMRI/Ultrasound fusion guided technology within urological units.

However, the urological community is still unable to dispense safely with prostatic biopsy, although imaging for gland/lesion characterization and targeted sampling are clearly beneficial. Continued refinements of mpMRI technique, with standardization of image interpretation are still required. The addition of genetic/serum markers may also help to reassure the clinician and the patient that their disease is truly low-risk but large-scale validation of these tests are needed. Ultimately, the acid test for future diagnostics will be their ability to define the “grey area” between the diagnostic categories more clearly, thereby turning the art of diagnosis and risk stratification into a more exact science.

Acknowledgements

None.

Financial support and sponsorship

This work was supported by the Belfast-Manchester Movember Centre of Excellence (CE013_2-004), funded in partnership with Prostate Cancer UK to N.W.C and by start-up fund from CRUK to E.B.

Conflicts of interest

There are no conflicts of interest.

Table 1: Select biomarkers with their sensitivity and specificity for distinguishing clinically significant prostate cancer.

Test name (reference) and cut-offs if applicable	Number of patients	CS cancer definition	Sensitivity (%)	Specificity (%)
PSA (21)	5575	Gleason ≥ 7 on biopsy		
1.1			92.8	37
3.1			57.6	82.3
4.1			40.4	90
6.1			13.2	97.8
4KScore Panel (22)	1012	Gleason ≥ 7		
≥ 6			94.4	39.3
≥ 15			79.2	75.7
PHI (23)	1157	Gleason ≥ 7	90	17
PCA3 (24)	305	Gleason ≥ 7		
>24			78.3	46.4
>35			63.8	57.1
mpMRI (25-27)	1981 (25)	Meta-analysis comprising different definitions of clinically significant cancer	58-96	23-87
		Tumor size $\geq 0.5\text{cc}$ or $\geq 1\text{cm}$ diameter	77.85	72.95
	297 (26, 27)	Gleason ≥ 7	79.76	71.36

CS- Clinically significant, PSA – Prostate specific antigen, PHI – Prostate health index, mpMRI – multiparametric magnetic resonance imaging, RP- Radical prostatectomy

Table 2: Potential role of different biomarkers in evolving diagnostic pathway of prostate cancer.

Pre-diagnosis		Post-diagnosis
Initial biopsy	Re-Biopsy	Prognostic markers
PSA or mpMRI or percent free PSA or PCA3 or PHI or 4Kscore	mpMRI and/or PSA, 4Kscore, PHI, PCA3, percent free PSA	Oncotype DX or Prolaris
mpMRI – multiparametric magnetic resonance imaging, PHI- prostate health index		

References

1. Siegel RL, Director SI, Surveillance and Health Services Research, American Cancer Society Atlanta GA, Miller KD, Surveillance and Health Services Research ACSEAG, Jemal A, Surveillance and Health Services Research ACSVPAG. Cancer statistics, 2015. CA: a cancer journal for clinicians. 2017;65(1):5-29.
2. Hamdy FC, Donovan JL, Lane JA, Mason M, Metcalfe C, Holding P, et al. 10-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Localized Prostate Cancer. The New England journal of medicine. 2016;375(15):1415-24.
3. Franks LM. Latent carcinoma of the prostate. The Journal of pathology and bacteriology. 1954;68(2):603-16.
4. Wilt TJ, Brawer MK, Jones KM, Barry MJ, Aronson WJ, Fox S, et al. Radical prostatectomy versus observation for localized prostate cancer. The New England journal of medicine. 2012;367(3):203-13.
5. Tosoian JJ, Carter HB, Lepor A, Loeb S. Active Surveillance for Prostate Cancer: Contemporary State of Practice. Nat Rev Urol. 2016;13(4):205-15.
6. Mottet N, Bellmunt J, Bolla M, Briers E, Cumberbatch MG, De Santis M, et al. EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent. Eur Urol. 2016.
7. Excellence NfHaC. Prostate cancer: diagnosis and management: NICE; 2017 [Available from: <https://www.nice.org.uk/guidance/CG175>].
8. Carroll PR, Parsons JK, Andriole G, Bahnson RR, Castle EP, Catalona WJ, et al. NCCN Guidelines Insights: Prostate Cancer Early Detection, Version 2.2016. Journal of the National Comprehensive Cancer Network : JNCCN. 2016;14(5):509-19.
9. Roobol MJ, Zhu X, Schroder FH, van Leenders GJ, van Schaik RH, Bangma CH, et al. A Calculator for Prostate Cancer Risk 4 Years After an Initially Negative Screen: Findings from ERSPC Rotterdam. Eur Urol. 2013;63(4):627-33.
10. Gronberg H, Adolfsson J, Aly M, Nordstrom T, Wiklund P, Brandberg Y, et al. Prostate cancer screening in men aged 50-69 years (STHLM3): a prospective population-based diagnostic study. The Lancet Oncology. 2015;16(16):1667-76.
11. Powell IJ, Bock CH, Ruterbusch JJ, Sakr W. Evidence supports a faster growth rate and/or earlier transformation to clinically significant prostate cancer in black than in white American men, and influences racial progression and mortality disparity. The Journal of urology. 2010;183(5):1792-6.
12. Randazzo M, Muller A, Carlsson S, Eberli D, Huber A, Grobholz R, et al. A positive family history as a risk factor for prostate cancer in a population-based study with organised prostate-specific antigen screening: results of the Swiss European Randomised Study of Screening for Prostate Cancer (ERSPC, Aarau). BJU Int. 2016;117(4):576-83.
13. Plonis J, Nakazawa-Miklasevica M, Malevskis A, Vaganovs P, Pildava S, Vjaters E, et al. Survival rates of familial and sporadic prostate cancer patients. Experimental oncology. 2015;37(2):154-5.
14. Raheem OA, Cohen SA, Parsons JK, Palazzi KL, Kane CJ. A Family History of Lethal Prostate Cancer and Risk of Aggressive Prostate Cancer in Patients Undergoing Radical Prostatectomy. Scientific reports. 2015;5:10544.
15. Ryan S, Jenkins MA, Win AK. Risk of prostate cancer in Lynch syndrome: a systematic review and meta-analysis. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology. 2014;23(3):437-49.
16. Moran A, O'Hara C, Khan S, Shack L, Woodward E, Maher ER, et al. Risk of cancer other than breast or ovarian in individuals with BRCA1 and BRCA2 mutations. Familial cancer. 2012;11(2):235-42.
17. Agalliu I, Gern R, Leanza S, Burk RD. Associations of high-grade prostate cancer with BRCA1 and BRCA2 founder mutations. Clinical cancer research : an official journal of the American Association for Cancer Research. 2009;15(3):1112-20.

18. Narod SA, Neuhausen S, Vichodez G, Armel S, Lynch HT, Ghadirian P, et al. Rapid progression of prostate cancer in men with a BRCA2 mutation. *Br J Cancer*. 2008;99(2):371-4.
19. Mitra AV, Bancroft EK, Barbachano Y, Page EC, Foster CS, Jameson C, et al. Targeted prostate cancer screening in men with mutations in BRCA1 and BRCA2 detects aggressive prostate cancer: preliminary analysis of the results of the IMPACT study. *BJU Int*. 2011;107(1):28-39.
20. Thompson IM, Pauler DK, Goodman PJ, Tangen CM, Lucia MS, Parnes HL, et al. Prevalence of prostate cancer among men with a prostate-specific antigen level ≤ 4.0 ng per milliliter. *The New England journal of medicine*. 2004;350(22):2239-46.
21. Thompson IM, Ankerst DP, Chi C, Lucia MS, Goodman PJ, Crowley JJ, et al. Operating characteristics of prostate-specific antigen in men with an initial PSA level of 3.0 ng/ml or lower. *Jama*. 2005;294(1):66-70.
22. Parekh DJ, Punnen S, Sjoberg DD, Asroff SW, Bailen JL, Cochran JS, et al. A Multi-institutional Prospective Trial in the USA Confirms that the 4Kscore Accurately Identifies Men with High-grade Prostate Cancer. *European Urology*. 2016;68(3):464-70.
23. Wang W, Wang M, Wang L, Adams TS, Tian Y, Xu J. Diagnostic ability of %p2PSA and prostate health index for aggressive prostate cancer: a meta-analysis. *Scientific Reports*, Published online: 23 May 2014; | doi:10.1038/srep05012. 2014.
24. Auprich M, Chun FK, Ward JF, Pummer K, Babaian R, Augustin H, et al. Critical assessment of preoperative urinary prostate cancer antigen 3 on the accuracy of prostate cancer staging. *Eur Urol*. 2011;59(1):96-105.
25. Futterer JJ, Briganti A, De Visschere P, Emberton M, Giannarini G, Kirkham A, et al. Can Clinically Significant Prostate Cancer Be Detected with Multiparametric Magnetic Resonance Imaging? A Systematic Review of the Literature. *Eur Urol*. 2015;68(6):1045-53.
26. Le JD, Tan N, Shkolyar E, Lu DY, Kwan L, Marks LS, et al. Multifocality and prostate cancer detection by multiparametric magnetic resonance imaging: correlation with whole-mount histopathology. *Eur Urol*. 2015;67(3):569-76.
27. Bratan F, Niaf E, Melodelima C, Chesnais AL, Souchon R, Mege-Lechevallier F, et al. Influence of imaging and histological factors on prostate cancer detection and localisation on multiparametric MRI: a prospective study. *European radiology*. 2013;23(7):2019-29.
28. Morgan TO, Jacobsen SJ, McCarthy WF, Jacobson DJ, McLeod DG, Moul JW. Age-specific reference ranges for prostate-specific antigen in black men. *The New England journal of medicine*. 1996;335(5):304-10.
29. Oesterling JE, Jacobsen SJ, Chute CG, Guess HA, Girman CJ, Panser LA, et al. Serum prostate-specific antigen in a community-based population of healthy men. Establishment of age-specific reference ranges. *Jama*. 1993;270(7):860-4.
30. Vickers AJ, Till C, Tangen CM, Lilja H, Thompson IM. An empirical evaluation of guidelines on prostate-specific antigen velocity in prostate cancer detection. *Journal of the National Cancer Institute*. 2011;103(6):462-9.
31. D'Amico AV, Renshaw AA, Sussman B, Chen MH. Pretreatment PSA velocity and risk of death from prostate cancer following external beam radiation therapy. *Jama*. 2005;294(4):440-7.
32. Radwan MH, Yan Y, Luly JR, Figenschau RS, Brandes SB, Bhayani SB, et al. Prostate-specific antigen density predicts adverse pathology and increased risk of biochemical failure. *Urology*. 2007;69(6):1121-7.
33. Lee R, Localio AR, Armstrong K, Malkowicz SB, Schwartz JS. A meta-analysis of the performance characteristics of the free prostate-specific antigen test. *Urology*. 2006;67(4):762-8.
34. Punnen S, Pavan N, Parekh DJ. Finding the Wolf in Sheep's Clothing: The 4Kscore Is a Novel Blood Test That Can Accurately Identify the Risk of Aggressive Prostate Cancer. *Rev Urol*. 2015;17(1):3-13.

35. Marks LS, Fradet Y, Deras IL, Blase A, Mathis J, Aubin SM, et al. PCA3 molecular urine assay for prostate cancer in men undergoing repeat biopsy. *Urology*. 2007;69(3):532-5.
36. Liss MA, Santos R, Osann K, Lau A, Ahlering TE, Ornstein DK. PCA3 molecular urine assay for prostate cancer: association with pathologic features and impact of collection protocols. *World journal of urology*. 2011;29(5):683-8.
37. Hessels D, van Gils MP, van Hooij O, Jannink SA, Witjes JA, Verhaegh GW, et al. Predictive value of PCA3 in urinary sediments in determining clinico-pathological characteristics of prostate cancer. *Prostate*. 2010;70(1):10-6.
38. Nam RK, Sugar L, Yang W, Srivastava S, Klotz LH, Yang LY, et al. Expression of the TMPRSS2:ERG fusion gene predicts cancer recurrence after surgery for localised prostate cancer. *Br J Cancer*. 972007. p. 1690-5.
39. Pettersson A, Graff RE, Bauer SR, Pitt MJ, Lis RT, Stack EC, et al. The TMPRSS2:ERG rearrangement, ERG expression, and prostate cancer outcomes: a cohort study and meta-analysis. *Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology*. 2012;21(9):1497-509.
40. Berg KD, Vainer B, Thomsen FB, Roder MA, Gerds TA, Toft BG, et al. ERG protein expression in diagnostic specimens is associated with increased risk of progression during active surveillance for prostate cancer. *Eur Urol*. 2014;66(5):851-60.
41. Tomlins SA, Day JR, Lonigro RJ, Hovelson DH, Siddiqui J, Kunju LP, et al. Urine TMPRSS2:ERG Plus PCA3 for Individualized Prostate Cancer Risk Assessment. *Eur Urol*. 2016;70(1):45-53.
42. Excellence NfHaC. Diagnosing prostate cancer: PROGENSA PCA3 assay and Prostate Health Index.: Status; 2015 [Available from: <https://www.nice.org.uk/guidance/dg17>].
43. Gleason DF. Classification of prostatic carcinomas. *Cancer chemotherapy reports*. 1966;50(3):125-8.
44. Epstein JI, Egevad L, Amin MB, Delahunt B, Srigley JR, Humphrey PA. The 2014 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma: Definition of Grading Patterns and Proposal for a New Grading System. *The American journal of surgical pathology*. 2016;40(2):244-52.
45. Berney DM, Beltran L, Fisher G, North BV, Greenberg D, Møller H, et al. Validation of a contemporary prostate cancer grading system using prostate cancer death as outcome. *British Journal of Cancer*. 2016;114(10):1078-83.
46. Epstein JI, Zelefsky MJ, Sjöberg DD, Nelson JB, Egevad L, Magi-Galluzzi C, et al. A Contemporary Prostate Cancer Grading System: A Validated Alternative to the Gleason Score. *European Urology*. 2016;69(3):428-35.
47. Loeb S, Folkvaljon Y, Robinson D, Lissbrant IF, Egevad L, Stattin P. Evaluation of the 2015 Gleason Grade Groups in a Nationwide Population-based Cohort. *European Urology*. 2016;69(6):1135-41.
- *48. Rubin MA, Girelli G, Demichelis F. Genomic Correlates to the Newly Proposed Grading Prognostic Groups for Prostate Cancer. *Eur Urol*. 2016;69(4):557-60.
This article describes genomic correlations to the new prognostic gleason grade groups.
49. Jennifer Cullena ILR, Timothy C. Brandc, Nan Zhangd, Athanasios C. Tsiatisd, Joel Moncurb, Amina Alia, Yongmei Chena, Dejan Knezevicd, Tara Maddalad, H. Jeffrey Lawrenced, Phillip G. Febbod, Shiv Srivastavaa, Isabell A. Sesterhenne, David G. McLeodb. A Biopsy-based 17-gene Genomic Prostate Score Predicts Recurrence After Radical Prostatectomy and Adverse Surgical Pathology in a Racially Diverse Population of Men with Clinically Low- and Intermediate-risk Prostate Cancer. 2015;68(1):123–31.
50. Knezevic D, Goddard AD, Natraj N, Cherbavaz DB, Clark-Langone KM, Snable J, et al. Analytical validation of the Onco type DX prostate cancer assay – a clinical RT-PCR assay optimized for prostate needle biopsies. *BMC Genomics*. 2013;14(1):690.

51. Weinreb JC, Barentsz JO, Choyke PL, Cornud F, Haider MA, Macura KJ, et al. PI-RADS Prostate Imaging – Reporting and Data System: 2015, Version 2. *European Urology*. 2017;69(1):16-40.
52. Rosenkrantz AB, Oto A, Turkbey B, Westphalen AC. Prostate Imaging Reporting and Data System (PI-RADS), Version 2: A Critical Look. *AJR American journal of roentgenology*. 2016;206(6):1179-83.
53. Muller BG, Shih JH, Sankineni S, Marko J, Rais-Bahrami S, George AK, et al. Prostate Cancer: Interobserver Agreement and Accuracy with the Revised Prostate Imaging Reporting and Data System at Multiparametric MR Imaging. *Radiology*. 2015;277(3):741-50.
54. Vargas HA, Hotker AM, Goldman DA, Moskowitz CS, Gondo T, Matsumoto K, et al. Updated prostate imaging reporting and data system (PI-RADS v2) recommendations for the detection of clinically significant prostate cancer using multiparametric MRI: critical evaluation using whole-mount pathology as standard of reference. *European radiology*. 2016;26(6):1606-12.
55. Schoots IG, Petrides N, Giganti F, Bokhorst LP, Rannikko A, Klotz L, et al. Magnetic Resonance Imaging in Active Surveillance of Prostate Cancer: A Systematic Review. *European Urology*. 2017;67(4):627-36.
56. Tran GN, Leapman MS, Nguyen HG, Cowan JE, Shinohara K, Westphalen AC, et al. Magnetic Resonance Imaging–Ultrasound Fusion Biopsy During Prostate Cancer Active Surveillance. *European Urology*. 2017.
57. Hashim Uddin Ahmed AE-SB, Louise C Brown, Richard S. Kaplan, Yolanda Colaco-Moraes, Katie Ward, Richard G Hindley, Alex Freeman, Alex K Kirkham, Robert Oldroyd, Rhian Gabe, Chris C. Parker, Mark Emberton, PROMIS Study Group. The PROMIS study: A paired-cohort, blinded confirmatory study evaluating the accuracy of multi-parametric MRI and TRUS biopsy in men with an elevated PSA. *J Clin Oncol* 34, 2016 (suppl; abstr 5000). 2016.
- *58. Ahmed HU, El-Shater Bosaily A, Brown LC, Gabe R, Kaplan R, Parmar MK, et al. Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confirmatory study. *The Lancet*. 2017.
Results from PROMIS trial evaluating the accuracy of MRI and TRUS biopsy.
59. Siddiqui MM, Rais-Bahrami S, Turkbey B, George AK, Rothwax J, Shakir N, et al. Comparison of MR/ultrasound fusion-guided biopsy with ultrasound-guided biopsy for the diagnosis of prostate cancer. *Jama*. 2015;313(4):390-7.
60. Wegelin O, Melick HHEv, Hooft L, Bosch JLHR, Reitsma HB, Barentsz JO, et al. Comparing Three Different Techniques for Magnetic Resonance Imaging-targeted Prostate Biopsies: A Systematic Review of In-bore versus Magnetic Resonance Imaging-transrectal Ultrasound fusion versus Cognitive Registration. Is There a Preferred Technique? *European Urology*. 2017.
61. Andreoiu M, Cheng L. Multifocal prostate cancer: biologic, prognostic, and therapeutic implications. *Human pathology*. 2010;41(6):781-93.
62. Cooper CS, Eeles R, Wedge DC, Loo PV, Gundem G, Alexandrov LB, et al. Analysis of the genetic phylogeny of multifocal prostate cancer identifies multiple independent clonal expansions in neoplastic and morphologically normal prostate tissue. *Nature genetics*. 2015;47:367-72.
63. Boutros PC, Fraser M, Harding NJ, de Borja R, Trudel D, Lalonde E, et al. Spatial genomic heterogeneity within localized, multifocal prostate cancer. *Nature genetics*. 2015;47(7):736-45.
64. Liu W, Laitinen S, Khan S, Vihinen M, Kowalski J, Yu G, et al. Copy number analysis indicates monoclonal origin of lethal metastatic prostate cancer. *Nat Med*. 15. United States 2009. p. 559-65.
65. Reichard CA, Klein EA. Clinical and molecular rationale to retain the cancer descriptor for Gleason score 6 disease. *Nature Reviews Urology*. 2016;14:59-64.
66. Miah S, Ahmed HU, Freeman A, Emberton M. Does true Gleason pattern 3 merit its cancer descriptor? *Nature Reviews Urology*. 2016;13:541-8.
67. Gburek BM, Kollmorgen TA, Qian J, D'Souza-Gburek SM, Lieber MM, Jenkins RB. Chromosomal anomalies in stage D1 prostate adenocarcinoma primary tumors and lymph node metastases detected by fluorescence in situ hybridization. *The Journal of urology*. 1997;157(1):223-7.

68. Ruijter ET, van de Kaa CA, Schalken JA, Debruyne FM, Ruiter DJ. Histological grade heterogeneity in multifocal prostate cancer. Biological and clinical implications. *The Journal of pathology*. 1996;180(3):295-9.
69. Hong MK, Macintyre G, Wedge DC, Van Loo P, Patel K, Lunke S, et al. Tracking the origins and drivers of subclonal metastatic expansion in prostate cancer. *Nature communications*. 2015;6:6605.
- *70. Wei L, Wang J, Lampert E, Schlanger S, DePriest AD, Hu Q, et al. Intratumoral and Intertumoral Genomic Heterogeneity of Multifocal Localized Prostate Cancer Impacts Molecular Classifications and Genomic Prognosticators. *European Urology*. 2016;71(2):183-92.
- This article reports on the implications of intra-prostate and intra tumor heterogeneity on genomic testing.
71. Lepor H. Using the 4Kscore Test and Magnetic Resonance Imaging Results to Avoid Unnecessary Prostate Biopsy. *Rev Urol*. 2015;17(1):1-2.
72. Fenstermaker M, Mendhiratta N, Bjurlin MA, Meng X, Rosenkrantz AB, Huang R, et al. Risk Stratification by Urinary Prostate Cancer Gene 3 Testing Before Magnetic Resonance Imaging-Ultrasound Fusion-targeted Prostate Biopsy Among Men With No History of Biopsy. *Urology*. 2017;99:174-9.
73. Gnanapragasam VJ, Burling K, George A, Stearn S, Warren A, Barrett T, et al. The Prostate Health Index adds predictive value to multi-parametric MRI in detecting significant prostate cancers in a repeat biopsy population. *Sci Rep*. 2016;6:35364.
74. Nicholson A, Mahon J, Boland A, Beale S, Dwan K, Fleeman N, et al. The clinical effectiveness and cost-effectiveness of the PROGENSA(R) prostate cancer antigen 3 assay and the Prostate Health Index in the diagnosis of prostate cancer: a systematic review and economic evaluation. *Health Technol Assess*. 2015;19(87):i-xxxi, 1-191.
75. De Luca S, Passera R, Cattaneo G, Manfredi M, Mele F, Fiori C, et al. High prostate cancer gene 3 (PCA3) scores are associated with elevated Prostate Imaging Reporting and Data System (PI-RADS) grade and biopsy Gleason score, at magnetic resonance imaging/ultrasonography fusion software-based targeted prostate biopsy after a previous negative standard biopsy. *BJU Int*. 2016;118(5):723-30.
76. Tosoian JJ, Druskin SC, Andreas D, Mullane P, Chappidi M, Joo S, et al. Use of the Prostate Health Index for detection of prostate cancer: results from a large academic practice. *Prostate Cancer Prostatic Dis*. 2017.
77. Rosenkrantz AB, Verma S, Choyke P, Eberhardt SC, Eggener SE, Gaitonde K, et al. Prostate Magnetic Resonance Imaging and Magnetic Resonance Imaging Targeted Biopsy in Patients with a Prior Negative Biopsy: A Consensus Statement by AUA and SAR. *J Urol*. 2016;196(6):1613-8.